Focused On-demand Library for Glutamate receptor ionotropic, kainate 2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q13002

UPID:
GRIK2_HUMAN

ALTERNATIVE NAMES:
Excitatory amino acid receptor 4; Glutamate receptor 6

ALTERNATIVE UPACC:
Q13002; A6NMY9; B5MCV0; D7RWZ3; D7RWZ4; D7RWZ5; D7RWZ6; D7RWZ7; Q8WWS1; Q96KS6; Q96KS7; Q96KS8

BACKGROUND:
The Glutamate receptor ionotropic, kainate 2, known alternatively as Excitatory amino acid receptor 4 or Glutamate receptor 6, is crucial for synaptic transmission in the brain, acting as an excitatory neurotransmitter receptor. Beyond its primary function, it also serves as a thermoreceptor for cold, indicating its diverse physiological roles.

THERAPEUTIC SIGNIFICANCE:
Linked to severe neurodevelopmental disorders, including Intellectual developmental disorder, autosomal recessive 6, and a disorder with impaired language and ataxia, the study of Glutamate receptor ionotropic, kainate 2 holds promise for novel therapeutic interventions. Its multifaceted role in biological systems makes it an intriguing subject for scientific inquiry and drug development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.